CDSCO Orders Dr. Reddy's to Revise Vonoprazan Phase IV Trial Protocol Over Inadequate Sample Size
核心洞察
India's drug regulatory committee has directed Dr. Reddy's Laboratories to justify and revise the sample size for its Phase IV clinical trial of vonoprazan tablets, citing the proposed patient numbers as "too small" for post-market safety assessment.
The Subject Expert Committee (搜索) specifically noted the absence of defined patient enrollment numbers for the 20 mg dose strength, which they identified as a more important target for the Phase IV study.
Dr. Reddy's has been given 15 days to submit a revised protocol with justified sample sizes for both 10 mg and 20 mg strengths of the potassium-competitive acid blocker (搜索) used for acid peptic disorders (搜索).
India's Central Drug Standard Control Organisation (搜索) (CDSCO (搜索)) has ordered Dr. Reddy's Laboratories to revise its Phase IV clinical trial protocol for vonoprazan tablets after determining that the proposed sample size is inadequate for post-market safety assessment. The Subject Expert Committee (搜索) (SEC) functioning under CDSCO has given the pharmaceutical company 15 days to justify patient enrollment numbers and submit a revised protocol.
Regulatory Concerns Over Study Design
The SEC's decision came after reviewing Dr. Reddy's Phase IV clinical trial protocol titled "A Phase-IV Study to Assess the Safety and Effectiveness of Vonoprazan 10/20mg in Adult Patients with Acid Peptic Disorders (搜索)" (Protocol no. DRL/VONO/2025-01, Version no.: 0, Dated: 24-06-2025). The expert panel identified critical deficiencies in the study design during their recent gastroenterology and hepatology meeting.
"The proposed sample size is too small considering that this is a Phase IV trial," the committee noted in its deliberations. The regulatory body expressed particular concern about the lack of specified sample size for the 20 mg dose strength, stating that this "is a more important target for this phase IV study."
Conditional Approval Requirements
Vonoprazan Tablets 10 mg and 20 mg were previously approved for manufacturing and marketing under specified conditions, with the Phase IV study requirement being a mandatory component of the approval. The post-market study is designed to further assess safety and effectiveness in adult patients with acid peptic disorders (搜索).
"In line with the condition of permission for manufacturing and marketing of Vonoprazan Tablets 10 mg/20 mg, the firm presented the Phase IV clinical trial protocol before the Committee," according to the meeting minutes.
Drug Profile and Therapeutic Use
Vonoprazan is a potassium-competitive acid blocker (搜索) used in the treatment of acid-related disorders (搜索) and serves as an adjunct to Helicobacter pylori (搜索) eradication therapy. The drug represents a newer class of acid suppressants that work differently from traditional proton pump inhibitors.
Next Steps for Dr. Reddy's
The committee has directed Dr. Reddy's Laboratories to address the identified deficiencies by submitting a comprehensive justification for the proposed sample size. The company must also clearly define the number of patients to be enrolled for each strength (10 mg and 20 mg) and provide a revised protocol within the 15-day deadline for further committee review.
The regulatory action underscores CDSCO (搜索)'s commitment to ensuring adequate post-market surveillance for newly approved medications, particularly for Phase IV studies that are critical for understanding real-world safety and effectiveness profiles in broader patient populations.